Pulmatrix, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pulmatrix, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel inhaled therapeutic products designed to prevent and treat migraine and respiratory diseases using its proprietary dry powder delivery technology, iSPERSE™. The company's core product pipeline includes PUR3100, a Phase 2-ready acute migraine treatment; PUR1800 for acute exacerbations of chronic obstructive pulmonary disease (AECOPD); and PUR1900 targeting allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma and cystic fibrosis. Pulmatrix's iSPERSE technology enables the formulation of small, dense, and dispersible particles to optimize drug delivery for deep lung penetration, aiming to improve pharmacokinetics and reduce systemic side effects. The company operates primarily in the United States and focuses on therapies for serious pulmonary and central nervous system disorders. Founded in 2005, Pulmatrix is headquartered in Lexington, Massachusetts. Recent major developments include a proposed merger agreement with Cullgen Inc., a clinical-stage biopharmaceutical company focused on targeted protein degrader therapies for cancer and pain. This merger, anticipated to close in the first half of 2025, aims to create a Nasdaq-listed entity combining Pulmatrix's inhalation platform with Cullgen's uSMITE™ platform for targeted protein degradation. As part of the merger strategy, Pulmatrix plans to divest its proprietary dry powder delivery assets, including its investigational migraine product PUR3100 and other candidates based on the iSPERSE technology. In 2025, Pulmatrix also completed wind-down activities for PUR1900 and closed licensing transactions for its iSPERSE technology with MannKind Corporation. The company amended its partnership with Cipla, which assumed development of PUR1900 outside the U.S., and focused on maximizing shareholder value through strategic alternatives while maintaining a cash runway into late 2026. Pulmatrix's business segments encompass developing inhaled therapeutics for respiratory diseases and migraine treatment, targeting patient populations with unmet medical needs. The company's strategic focus shifting through divestment and merger plans reflects its transformation towards an integrated biopharmaceutical entity advancing novel therapies in targeted protein degradation alongside inhalation therapeutics. Pulmatrix continues to prioritize advancing clinical-stage assets and expanding its technology platform collaboration footprint to optimize therapeutic outcomes for serious diseases.
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--PULM, SLP, OLN, and HUN
Pulmatrix Announces First Quarter 2026 Financial Results
Pulmatrix Announces First Quarter 2026 Financial Results
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders
Pulmatrix (NASDAQ:PULM) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
Pulmatrix (NASDAQ:PULM) Share Price Crosses Below 50 Day Moving Average – What’s Next?
INmune Bio (NASDAQ:INMB) & Pulmatrix (NASDAQ:PULM) Head-To-Head Review
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
Pulmatrix (NASDAQ:PULM) Stock Price Passes Below 50-Day Moving Average – Here’s Why
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
Pulmatrix (PULM) Q2 Revenue Falls 100%
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets
PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders